Table 1 Baseline characteristics of patients (n = 272)
Characteristic | n (%) |
|---|---|
Age at diagnosis, years, median [IQR] | 63.2 [52.0;73.0] |
Age at metastasis, years, median [IQR] | 67.0 [55.0;75.0] |
Male sex, n (%) | 172 (63.2) |
Basal LDH, n (%) | |
Normal | 171 (62.87) |
Increased | 79 (29) |
Not available | 22 (8.1) |
Mutational status | |
BRAF/NRAS wild type | 145 (53.3) |
NRAS mutated | 127 (46.7) |
N of metastatic sites < 3, n (%) | 169 (62.1) |
Site of melanoma | |
Cutaneous | 210 (77.2) |
Mucosal | 19 (7) |
Ocular | 14 (5.1) |
Unknown | 29 (10.7) |
Prior adjuvant therapy | 20 (7.3%) |
ECOG PS | |
0 | 192 (70.6) |
1 | 78 (28.7) |
2 | 2 (0.7) |
Stage at metastatic disease (AJCC VIII edition) | |
M1a | 66 (24.3) |
M1b | 77 (28.3) |
M1c | 102 (37.5) |
M1d | 27 (9.9) |
First line therapy | |
Anti-PD-1 | 209 (76.8) |
Anti-CTLA-4 | 57 (20.9) |
Anti-PD-1 + Anti-CTLA-4 | 6 (2.2) |